NUCEL GROUP OF CELLULAR AND MOLECULAR THERAPY

Graduated in Biomedical Sciences from the Institute of Biomedical Sciences of the University of São Paulo (ICB-USP), completed in 2019. Currently, he is studying Postgraduate Studies (Direct Doctorate) in the Postgraduate Program in Biological Sciences (Biochemistry) of the Institute of Chemistry at the University of São Paulo (IQ-USP). During his graduation, he developed a Scientific Initiation project, with a FAPESP grant, at the Nucleus of Cellular and Molecular Therapy (NUCEL) of the University of São Paulo, with an emphasis on the production and molecular improvement of biopharmaceuticals in mammalian cells. He also acted as a FAPESP Laboratory Technician (BCO / TT-3 modality), assisting in the experiments of the current FAPESP Thematic Project in the laboratory. Currently he works as a postgraduate researcher at the NUCEL Group, developing projects with an emphasis on Protein Engineering and Glyco-Engineering of cell lines for heterologous expression of biopharmaceuticals and recombinant proteins with therapeutic potential, such as prolactin and R-Spondin 1.

The projects developed by the researcher are related to two main lines of research:

1. Glyco-engineering and genetic modification of mammalian (CHO) and insect (Sf9) cell lines used for heterologous expression of human proteins.
2. Production of biopharmaceuticals and recombinant proteins with therapeutic potential in genetically modified cell lines.

Picture: CHO cells transduced with recombinant lentiviral vector, modified to express a biopharmaceutical along with the EGFP reporter gene, visualized by microscopy. A: Fluorescence microscopy. B: Phase contrast microscopy.